MorphoSys Trial for Blood-Cancer Treatment Reaches Primary Endpoint
21 11월 2023 - 7:19AM
Dow Jones News
By Ben Glickman
MorphoSys said its study of a treatment for myelofibrosis, a
rare form of blood cancer, reached its primary endpoint, clearing
the way for a new drug application in mid-2024.
The German pharmaceutical company said Monday its Phase 3 trial
of pelabresib in combination with ruxolitinib in myelofibrosis
patients found a statistically significant and clinically
meaningful improvement in the portion of patients with a 35% or
greater reduction in spleen volume after 24 weeks.
There was also a meaningful reduction in myelofibrosis symptoms,
a key secondary endpoint, according to the company.
MorphoSys now intends to submit a new drug application for
pelabresib in combination with ruxolitinib to U.S. and European
regulators in mid-2024.
The company's combination therapy received fast track
designation from the Food and Drug Administration in treating
myelofibrosis in 2018.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
November 20, 2023 17:04 ET (22:04 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
MorphoSys (NASDAQ:MOR)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025
MorphoSys (NASDAQ:MOR)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025
